Dietary Quercetin Reduces Plasma and Tissue Methylglyoxal and Advanced Glycation End Products in Healthy Mice Treated with Methylglyoxal

被引:15
|
作者
Zhao, Yantao [1 ]
Tang, Yao [1 ]
Sang, Shengmin [1 ]
机构
[1] North Carolina Agr & Tech State Univ, Ctr Excellence Postharvest Technol, Lab Funct Foods & Human Hlth, North Carolina Res Campus, Kannapolis, NC 28081 USA
来源
JOURNAL OF NUTRITION | 2021年 / 151卷 / 09期
基金
美国食品与农业研究所;
关键词
methylglyoxal; advanced glycation end products; quercetin; direct trapping; detoxification pathway; TRAPPING METHYLGLYOXAL; DIABETIC-NEPHROPATHY; DICARBONYL STRESS; DISEASE; OBESITY; AGES; NRF2;
D O I
10.1093/jn/nxab176
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Methylglyoxal (MGO), a precursor of advanced glycation end products (AGEs), has been linked to AGEs-associated diseases. Objectives: This study investigated the efficacy and mechanisms of dietary quercetin in decreasing plasma and tissue concentrations of MGO and AGEs in MGO-administered mice. Methods: Male, 6-wk-old CD-1 mice were administered AIN-93G diet and water (Con) or 0.12% MGO in water (MGO) or MGO plus 0.2% (0.20) dietary quercetin for 1 wk (n = 5) (experiment 1), and water (Con), 0.12% MGO (MGO), or MGO plus 0.1% (0.1Q), 0.2% (0.20), or 0.4% (0.4Q) dietary quercetin for 6 wk (n = 10) (experiment 2). The plasma, kidney, and liver concentrations of MGO, quercetin, and isorhamnetin and their trapping adducts with MGO were determined by LC-MS, and AGE concentrations were measured by the fluorescent method. Furthermore, the expressions of glyoxalase I/II (GLO I/II) and aldose reductase (AR), MGO detoxification enzymes, were determined by Western blot. One-factor ANOVA and post hoc Dunnett's or Tukey's test were used to analyze the data. Results: After 1 wk of treatment, the MGO concentrations in plasma (20.2%) and kidney (29.9%) in 0.20 mice were significantly lower than those in MGO mice. After 6 wk of treatment, the concentrations of MGO in the plasma (14.7-18.6%), kidney (20-20.8%), liver (15.4-18.6%), and tissue AGEs (28-36.8%) in 0.10, 0.20, and 0.40 mice were significantly lower than those in MGO mice. The plasma concentrations of quercetin, isorhamnetin, and their MGO adducts were dose-dependently increased after quercetin administration. In addition, after 6 wk of quercetin administration, the expressions of GLO I/II and AR in the liver and kidney were significantly upregulated to promote MGO detoxification compared with MGO-treated mice. Conclusions: Quercetin reduced plasma and tissue MGO concentrations and inhibited AGE formation by trapping MGO and regulating the MGO detoxification systems in MGO-administered healthy mice.
引用
收藏
页码:2601 / 2609
页数:9
相关论文
共 50 条
  • [31] Elevated plasma methylglyoxal and glyoxal in uraemia: implications for advanced glycation end-product formation.
    Mann, VM
    Tucker, B
    Thomalley, PJ
    Daynay, A
    KIDNEY INTERNATIONAL, 1999, 55 (06) : 2582 - 2582
  • [32] Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation
    Rodrigues, Lisa
    Matafome, Paulo
    Crisostomo, Joana
    Santos-Silva, Daniela
    Sena, Cristina
    Pereira, Paulo
    Seica, Raquel
    JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 2014, 70 (01) : 173 - 184
  • [33] Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation
    Lisa Rodrigues
    Paulo Matafome
    Joana Crisóstomo
    Daniela Santos-Silva
    Cristina Sena
    Paulo Pereira
    Raquel Seiça
    Journal of Physiology and Biochemistry, 2014, 70 : 173 - 184
  • [34] Protective effects against memory impairment induced by methylglyoxal in mice co-treated with FPS-ZM1, an advanced glycation end products receptor antagonist
    Szczepanik, Jozimar Carlos
    Garcia, Abel Freitas
    Lopes de Almeida, Gudrian Ricardo
    Cunha, Mauricio Pena
    Dafre, Alcir Luiz
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2020, 80 (04) : 364 - 374
  • [35] Inhibition of the formation of advanced glycation end products from methylglyoxal-modified ribonuclease by okra seed bioactives
    Dayal, Bishambar
    Gohil, Rajeshri
    Garsondiya, Bhaveshkumar
    Lea, Michael
    Nirujogi, Swayam Prabha
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [36] Methylglyoxal and Advanced Glycation End Products (AGEs): Targets for the Prevention and Treatment of Diabetes-Associated Bladder Dysfunction?
    Oliveira, Akila Lara
    de Oliveira, Mariana Goncalves
    Monica, Fabiola Zakia
    Antunes, Edson
    BIOMEDICINES, 2024, 12 (05)
  • [37] Methylglyoxal mediated conformational changes in histone H2A-generation of carboxyethylated advanced glycation end products
    Mir, Abdul Rouf
    Uddin, Moin
    Alam, Khursheed
    Ali, Asif
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2014, 69 : 260 - 266
  • [38] Methylglyoxal and Advanced Glycation End Products in Patients with Diabetes - What We Know so Far and the Missing Links
    Groener, Jan Benedikt
    Oikonomou, Dimitrios
    Cheko, Ruan
    Render, Zoltan
    Zemva, Johanna
    Kihm, Lars
    Muckenthaler, Martina
    Peters, Verena
    Fleming, Thomas
    Kopf, Stefan
    Nawroth, Peter P.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2019, 127 (08) : 497 - 504
  • [39] Circulating Concentrations of advanced Glycation end Products, Carboxymethyl Lysine and Methylglyoxal are Associated With Renal Function in Individuals With Diabetes
    Ding, Lina
    Hou, Yanli
    Liu, Junjun
    Wang, Xiaolei
    Wang, Zhibin
    Ding, Wenyu
    Zhao, Ke
    JOURNAL OF RENAL NUTRITION, 2024, 34 (02) : 154 - 160
  • [40] Methylglyoxal-Derived Advanced Glycation End Products Are Prognostic Biomarkers for Diabetic Complications and Drivers of Endothelial Dysfunction
    Lai, Seigmund
    Gonzalez, Edwin D. J. Lopez
    Shuck, Sarah
    DIABETES, 2023, 72